Sjögren's disease & overlap diseases
Systemic disease activity measured with ESSDAI varies largely over 5 years in a prospective, longitudinal cohort of patients with Sjögren’s disease
Authors' conclusion
In this cohort of patients with SjD, overall ESSDAI slightly decreased during 5 years of follow-up, whereas at individual patient level, large variation was seen over time for the majority of patients. Longer time in ESSDAI LDA was associated with better salivary gland outcomes.
Study context
- Population
- Patients with Sjögren's disease (SjD) fulfilling the 2016 ACR/EULAR classification criteria with ≥2 years of follow-up, in the REgistry of Sjögren Syndrome LongiTudinal cohort236 (89%) women
- Participants
- 265 patients
- Exposure
- ESSDAI low disease activity (LDA) for ≥75% vs <75% of time
- Outcome
- Variation in systemic disease activity (ESSDAI) over time at group and individual patient level
- Follow-up
- Up to 5 years
Methodological detailslongitudinal, standard-of-care cohort
- Longitudinal
- Standard-of-care cohort
Main finding
As reported in the abstract
ESSDAI over time (group level) · baseline to year 5
Median ESSDAI at baseline (IQR 2-7)
4
Median ESSDAI at year 5 (IQR 2-5)
3
Untreated patients with ESSDAI<5 at baseline changing to ESSDAI≥5 at least once
50 of 102
49%
Untreated patients with ESSDAI≥5 at baseline changing to ESSDAI<5
41 of 45
91%
Observational data: associations, not effects.
Further findings
Saliva production
- Better outcomes with ESSDAI LDA for ≥75% of time
Original publication
Systemic disease activity measured with ESSDAI varies largely over 5 years in a prospective, longitudinal cohort of patients with Sjögren’s disease. RMD Open. Published 22 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →